Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The global research community asks for the right research in the right places for COVID-19. The Global Health Network, the African Academy of Sciences and UK Collaborative on Development Research release a report in Nature that calls for the use of research evidence on the optimal implementation of public health interventions for COVID-19 in varied global settings.

Hand holding global network using modern medical and health care interface

In the absence of a vaccine and community-based treatment we are reliant on public health measures to stop this pandemic. From how to implement social distancing in urban informal settlements to how to gain trust and mitigate myths within communities. There is a clear and urgent need to further understand COVID-19.

The Global Health Network, The African Academy of Sciences and The UK Collaborative on Development Research have published findings of a global study to establish what are the remaining research priorities for COVID-19 and whether they are the same across the globe. A peer reviewed paper reporting these data has just been accepted for publication by BMJ Global, with a global perspective on this also being reported in Nature, today.

There is a finite window to undertake research within an outbreak. Scientists and researchers around the world have worked rapidly to increase understanding of COVID-19. But there are still many unknowns as the pandemic accelerates and spreads into new areas. Different studies are needed across the globe and the evidence must be tailored for different settings with the benefits from the research being equitable and widely accessible.

The full story is available on the Centre for Tropical Medicine & Global Health website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.